Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)

This study is called the LS-URO Study, which is short for "Lynch Syndrome Urothelial Cancer Screening." This research is about finding a better way to check for certain cancers in people who have Lynch syndrome. Lynch syndrome is a condition that you can inherit from your parents, and it means you have a higher chance of developing certain types of cancer during your life. The study focuses on cancers of the urinary tract, specifically bladder cancer and cancers in the tubes connecting the kidneys to the bladder.

These types of cancer, called urothelial cancers, are quite common in people with Lynch syndrome. In fact, up to one in four people with Lynch syndrome might develop one of these cancers. Finding these cancers early is really important because it means treatments are more likely to work well. At the moment, we don't have the very best ways to screen for these cancers in people with Lynch syndrome.

This study will try a new urine test. This test looks for tiny bits of cancer DNA in your urine. The idea is that if we can find these cancer clues in your urine before you even have any symptoms, doctors can step in sooner. We will compare this new urine DNA test with another type of urine test that is sometimes used now, called urine cytology. By doing this comparison, we hope to learn if the new test is better at catching these cancers early in people with Lynch syndrome, ultimately leading to better health outcomes.